OBJECTIVES:  Prostate cancer is one of the first most common malignancy in men and the second most common leading source of cancer deaths in Europe. The main objective of this study to estimate the overall prostate cancer prevalence and incidence in Hungary and to analyse prostate cancer patients’ survival in context of radical prostatectomy (RP). METHODS:  We performed a retrospective analysis in the database of the Hungarian National Health Insurance Found Administration which comprises longitudinal claims data for the whole population covering almost 10 million people. Patients were identified between 2002-2012 through a multi-step process based on international classification codes for prostate cancer and having either prostate biopsy or androgen-deprivation therapy or radical prostatectomy or radiotherapy. Survival were calculated for a cohort of patients diagnosed between 2002-2005. RESULTS:  In 2012, a total of 25,606 men with prostate cancer were alive and 3,300 of them were newly diagnosed case, representing a prevalence of 542 cases and an incidence of 70 cases per 100,000 men in Hungary. Mean (SD) age and disease duration were 75 (8.7) and 4.8 (3.5) years, respectively, and 1,448 (5.7%) patients had bone metastasis. In 2012, 672 (2.6%) patients were undergoing radical prostatectomy and 6,615 (25.8%) patients were on androgen-deprivation therapy. Overall mortality were 8.8% (2,246 cases). RP patients’ mean survival time was significantly longer both in the total sample (11.2 vs. 7.4 years; p<0.001) and in the subgroup under age of 70 years (11.3 vs 8.8 years; p<0.001). CONCLUSIONS: Our study offers nationwide epidemiological data on prostate cancer in Hungary. Better life-expectancy of RP patients could be explained by various factors. Except of younger age patients with radical prostatectomy might have different socio-economic characteristics and different access to health care compared to no RP patient group. Acknowledgement: This study was supported by Bolyai Research Scholarship of the Hungarian Academy of Sciences.